Advanced

Levodopa infusion in Parkinson's disease : Individual quality of life

Ehlers, Claas ; Timpka, Jonathan LU ; Odin, Per LU and Honig, Holger (2020) In Acta Neurologica Scandinavica
Abstract

Objectives: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of life (QoL). Levodopa-carbidopa intestinal gel (LCIG) reduces motor complications and improves some non-motor symptoms in advanced PD (APD). Change in patients' health-related quality of life (hrQoL) is a common endpoint in PD trials and has become an important factor in judging overall effect of LCIG. However, hrQoL is considered to be only one dimension of QoL. The primary aim of this prospective observational study was to observe the effects of LCIG on individual quality of life (iQoL) in PD and caregivers. The secondary aim was to investigate its effects on patients' motor and non-motor symptoms as well as effects on... (More)

Objectives: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of life (QoL). Levodopa-carbidopa intestinal gel (LCIG) reduces motor complications and improves some non-motor symptoms in advanced PD (APD). Change in patients' health-related quality of life (hrQoL) is a common endpoint in PD trials and has become an important factor in judging overall effect of LCIG. However, hrQoL is considered to be only one dimension of QoL. The primary aim of this prospective observational study was to observe the effects of LCIG on individual quality of life (iQoL) in PD and caregivers. The secondary aim was to investigate its effects on patients' motor and non-motor symptoms as well as effects on caregiver burden. Materials & Methods: Utilizing the Schedule for the Evaluation of Individual Quality of Life-Questionnaire (SEIQoL-Q) and the Personal Wellbeing Index-Adult (PWI-A), twelve patients with advanced PD and their caregivers were followed for six months after initiation of LCIG treatment. Results: At the final follow-up, improvements of iQoL for patients (median SEIQoL index improvement 0.16, P <.05) and caregivers (median SEIQoL index improvement 0.20, P <.05) were seen together with improvements of motor and non-motor symptoms. There were no significant improvements of hrQoL. Conclusions: The study results indicate that LCIG improves iQoL in PD in addition to the improvement of motor and non-motor symptoms. Furthermore, this study signals that LCIG may also contribute to improvement of iQoL in caregivers.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
caregiver, disease, duodenum, infusion, non-motor, Parkinson's, quality of life
in
Acta Neurologica Scandinavica
publisher
Wiley-Blackwell
external identifiers
  • pmid:32383152
  • scopus:85084969687
ISSN
0001-6314
DOI
10.1111/ane.13260
language
English
LU publication?
yes
id
8297c745-264c-4158-96f1-97e5e39e84ea
date added to LUP
2020-06-25 17:27:05
date last changed
2020-06-26 01:58:51
@article{8297c745-264c-4158-96f1-97e5e39e84ea,
  abstract     = {<p>Objectives: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of life (QoL). Levodopa-carbidopa intestinal gel (LCIG) reduces motor complications and improves some non-motor symptoms in advanced PD (APD). Change in patients' health-related quality of life (hrQoL) is a common endpoint in PD trials and has become an important factor in judging overall effect of LCIG. However, hrQoL is considered to be only one dimension of QoL. The primary aim of this prospective observational study was to observe the effects of LCIG on individual quality of life (iQoL) in PD and caregivers. The secondary aim was to investigate its effects on patients' motor and non-motor symptoms as well as effects on caregiver burden. Materials &amp; Methods: Utilizing the Schedule for the Evaluation of Individual Quality of Life-Questionnaire (SEIQoL-Q) and the Personal Wellbeing Index-Adult (PWI-A), twelve patients with advanced PD and their caregivers were followed for six months after initiation of LCIG treatment. Results: At the final follow-up, improvements of iQoL for patients (median SEIQoL index improvement 0.16, P &lt;.05) and caregivers (median SEIQoL index improvement 0.20, P &lt;.05) were seen together with improvements of motor and non-motor symptoms. There were no significant improvements of hrQoL. Conclusions: The study results indicate that LCIG improves iQoL in PD in addition to the improvement of motor and non-motor symptoms. Furthermore, this study signals that LCIG may also contribute to improvement of iQoL in caregivers.</p>},
  author       = {Ehlers, Claas and Timpka, Jonathan and Odin, Per and Honig, Holger},
  issn         = {0001-6314},
  language     = {eng},
  month        = {05},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Neurologica Scandinavica},
  title        = {Levodopa infusion in Parkinson's disease : Individual quality of life},
  url          = {http://dx.doi.org/10.1111/ane.13260},
  doi          = {10.1111/ane.13260},
  year         = {2020},
}